PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells $35,048.90 in Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) insider Deepika Jalota sold 33,065 shares of PMV Pharmaceuticals stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $35,048.90. Following the completion of the transaction, the insider owned 89,959 shares of the company's stock, valued at approximately $95,356.54. The trade was a 26.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

PMV Pharmaceuticals Stock Performance

NASDAQ:PMVP traded up $0.11 on Friday, reaching $1.21. The company's stock had a trading volume of 582,828 shares, compared to its average volume of 197,220. PMV Pharmaceuticals, Inc. has a 1-year low of $0.81 and a 1-year high of $1.82. The firm has a market cap of $62.86 million, a PE ratio of -1.03 and a beta of 1.49. The business's 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.19.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.03. As a group, sell-side analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of PMV Pharmaceuticals in a report on Thursday, March 20th.

Institutional Trading of PMV Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in PMV Pharmaceuticals by 2,282.8% in the fourth quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock valued at $37,000 after buying an additional 23,559 shares during the period. Velan Capital Investment Management LP bought a new position in shares of PMV Pharmaceuticals during the fourth quarter worth approximately $53,000. Squarepoint Ops LLC increased its stake in shares of PMV Pharmaceuticals by 68.7% during the fourth quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock worth $110,000 after purchasing an additional 29,722 shares during the period. Northern Trust Corp increased its stake in shares of PMV Pharmaceuticals by 23.2% during the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company's stock worth $162,000 after purchasing an additional 20,190 shares during the period. Finally, Bridgeway Capital Management LLC increased its stake in shares of PMV Pharmaceuticals by 44.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock worth $305,000 after purchasing an additional 62,200 shares during the period. Institutional investors own 90.20% of the company's stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.